Cilengitide

Generic Name: Cilengitide

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀N_₈O_₇

CAS Number: 188968-51-6

Unique Ingredient Identifier: 4EDF46E4GI

Background: Cilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Phase 1

Completed

Conditions: Childhood Central Nervous System Germ Cell Tumor
Childhood Choroid Plexus Tumor
Childhood Craniopharyngioma
Childhood Ependymoblastoma
Childhood Grade I Meningioma
Childhood Grade II Meningioma
Childhood Grade III Meningioma
Childhood High-grade Cerebellar Astrocytoma
Childhood High-grade Cerebral Astrocytoma
Childhood Infratentorial Ependymoma

Interventions: Drug: cilengitide
Other: laboratory biomarker analysis

First Posted Date: 2003-07-09

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00063973

Locations: 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States

EMD 121974 in Treating Patients With Progressive or Recurrent Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-24

Lead Sponsor: New Approaches to Brain Tumor Therapy Consortium

Registration Number: NCT00006093

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

and more 7 locations

EMD 121974 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cilengitide
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00022113

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy